Molecular Psychiatry (2001) 6 , 434–439 2001 Nature Publishing Group All rights reserved 1359-4184/01 $15.00 www.nature.com/mp ORIGINAL RESEARCH ARTICLE Role of the serotonin transporter gene in the behavioral expression of autism S Tordjman1,2, L Gutknecht1, M Carlier1, E Spitz1, C Antoine2, F Slama1, V Carsalade2, DJ Cohen3,P Ferrari2, PL Roubertoux1 and GM Anderson31FRE 2134 CNRS
sydneyrx2014.com Online ED Pharmacy is an 1st. pharmacy providing a personal service to the community in Australia. Over 50,000 extremely satisfied customers! We're your prescription drug store levitra australia and have provided trusted service to families in Australia for over 15 years.
Microsoft word - immunization and meningitis certificate 3 2 07.docCERTIFICATE OF IMMUNIZATION
MANDATORY NEW YORK STATE REQUIREMENTS FOR COLLEGE STUDENTS
Name: ___________________________________________ I.D. or Social Security Number ______________________________ Date of birth: ______________________________________ Semester Entering FLCC: __________________________________
Please note: According to NYS Public Health Law, students enrolling for six (6) or more credit hours (typically two courses) must
submit proof of immunity against measles, mumps and rubella (if born on or after January 1, 1957) and the meningitis response form below to Student Health Services prior to registering for classes. The student may be withdrawn from classes if this information is
not received in the Student Health Services’ office within 30 days of the beginning of the semester. Students admitted to the
A.A.S. Nursing or A.A.S. Therapeutic Massage/Integrated Health Care programs must complete special health forms included in their acceptance letters and do not submit this form.
MANDATORY IMMUNIZATIONS REQUIREMENTS FOR STUDENTS BORN ON OR AFTER JANUARY 1, 1957:
Health Care Provider (Physician/High School Nurse): complete the table below and sign at bottom of page OR attach signed
1st Dose 2nd Dose
1. Measles (Rubeola)
given 1968 or after. First dose on or
after 12 months of age. The second
dose on or after 15 months of age.
received on or after first birthday.
include certified lab results if vaccine date is unavailable.
MENINGITIS RESPONSE FORM (to be completed by all students enrolling for six or more credit hours)
Student: Please check one of the following responses below and sign and date:
__ I have read, or have had explained to me, the information (on reverse) regarding meningococcal meningitis
disease. I will not obtain immunization against meningococcal meningitis disease.
__ Menomune/Meningococcal meningitis vaccine date: ____________________________ Signed ___________________________________________________________ Date: ________________________________ (Parent or guardian must sign if student is under the age of 18)
The following immunizations are highly recommended but not mandatory. If the student has received any of these, please fill in below:
Tetanus-Diptheria - Date of Dose:_________________ PPD (Mantoux) Result: ________________ Date of Reading:____________________
Hepatitis B - Date of first dose: ___________________ Date of second dose: ___________________ Date of third dose: __________________
HEALTH CARE PROVIDER SIGNATURE: x _________________________________________________________________
Address: __________________________________________________________________________________________________ Phone: (_______)___________________ID Number: _________________________ Date: ______________________________
Return form to: Student Health Services, Finger Lakes Community College, 3325 Marvin Sands Dr., Canandaigua, NY 14424-8395.
Fax: (585)785-1612, Attn: Student Health Services (Faxes that are not readable or are not complete, cannot be used.) MENINGOCOCCAL MENINGITIS FACT SHEET
WHAT IS MENINGOCOCCAL MENINGITIS? Meningococcal disease is a severe bacterial infection of
the bloodstream or meninges (a thin lining covering the brain and spinal cord). It is a relatively rare
disease and usually occurs as a single isolated event. Clusters of cases or outbreaks are rare in the
HOW IS THE GERM MENINGOCOCCUS SPREAD? Meningococcal disease is transmitted through the
air via droplets of respiratory secretions and direct contact with an infected person. Direct contact, for
these purposes, is defined as oral contact with shared items such as cigarettes or drinking glasses or
through intimate contact such as kissing. Although anyone can come in contact with the bacteria that
causes meningococcal disease, data also indicates certain social behaviors, such as exposure to passive
and active smoking, bar patronage, and excessive alcohol consumption, may put students at increased
risk for the disease. Patients with respiratory infections, compromised immunity, those in close contact to
a known case, and travelers to endemic areas of the world are also at increased risk.
WHAT ARE THE SYMPTOMS? The early symptoms usually associated with meningococcal disease
include fever, severe headache, stiff neck, rash, nausea, vomiting, and lethargy, and may resemble the
flu. Because the disease progresses rapidly, often in as little as 12 hours, students are urged to seek
medical care immediately if they experience two or more of these symptoms concurrently. The disease is
HOW SOON DO THE SYMPTOMS APPEAR? The symptoms may appear two to 10 days after
exposure, but usually within five days.
WHAT IS THE TREATMENT FOR MENINGOCOCCAL DISEASE? Antibiotics, such as penicillin G or
ceftriaxone, can be used to treat people with meningococcal disease.
SHOULD PEOPLE WHO HAVE BEEN IN CONTACT WITH A DIAGNOSED CASE OF
MENINGOCOCCAL MENINGITIS BE TREATED? Only people who have been in close contact
(household members, intimate contacts, health care personnel performing mouth-to-mouth resuscitation,
day care center playmates, etc.) need to be considered for preventive treatment. Such people are usually
advised to obtain a prescription for a special antibiotic (either rifampin, ciprofloxacin or ceftriaxone) from
their physician. Casual contact as might occur in a regular classroom, office or factory setting is not
usually significant enough to cause concern.
IS THERE A VACCINE TO PREVENT MENINGOCOCCAL MENINGITIS? * Presently, there is a
vaccine that will protect against some of the strains of meningococcus. It is recommended in outbreak
situations, and for those traveling to areas of the world where high rates of the disease are known to
occur. For some college students, such as freshman living in dormitories, there is a modestly increased
risk of meningococcal disease; students and parents should be educated about meningococcal disease
and the availability of a safe and effective vaccine.
HOW EFFECTIVE IS THE VACCINE? The meningococcal vaccine has been shown to provide
protection against the most common strains of the disease, including serogroups A, C, Y and W-135. The
vaccine has shown to be 85 to 100 percent effective in serogroups A and C in older children and adults.
IS THE VACCINE SAFE? ARE THERE ADVERSE SIDE EFFECTS TO THE VACCINE? The vaccine is
very safe and adverse reactions are mild and infrequent, consisting primarily of redness and pain at the
site of injection lasting up to two days.
WHAT IS THE DURATION OF PROTECTION? The duration of the menactra vaccine is 10 years. The
menomune vaccine is effective for 3-5 years. * The vaccination is not available at Finger Lakes Community College. If you are interested in obtaining the vaccine, please call a
clinic for an appointment, cost and to determine if the vaccine is available:
Clinic and Location Phone
Ontario County Health Dept., 3019 County Complex Dr., Canandaigua, NY 1-800-299-2995
Monroe County Health Dept., 111 Westfall Rd., Rochester, NY (585)274-6000
Wayne County Health Dept., 1519 Nye Rd., Lyons, NY 1-800-724-1170
August 2003. Source: New York State Department of Health Website (Revised March 2003) and the American College Health
Genetic and expression analyses reveal elevated expression of syntaxin 1a ( stx1a) in high functioning autism
International Journal of Neuropsychopharmacology, Page 1 of 12. Copyright f 2008 CINPGenetic and expression analyses reveal elevatedexpression of syntaxin 1A (STX1A) in highfunctioning autismKazuhiko Nakamura1*, Ayyappan Anitha1*, Kazuo Yamada2*, Masatsugu Tsujii3,4,Yoshimi Iwayama2, Eiji Hattori2, Tomoko Toyota2, Shiro Suda1, Noriyoshi Takei1,Yasuhide Iwata1, Katsuaki Suzuki1, Hideo Matsuzak